

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/319338238>

Multimodality treatment of stage II thymic tumours

Article in *Journal of Thoracic Disease* · August 2017

DOI: 10.21037/jtd.2017.06.116

CITATIONS

3

READS

21

13 authors, including:



Ylenia Pecoraro

Sapienza University of Rome

14 PUBLICATIONS 82 CITATIONS

[SEE PROFILE](#)



Tiziano De Giacomo

Sapienza University of Rome

187 PUBLICATIONS 3,393 CITATIONS

[SEE PROFILE](#)



Camilla Poggi

Sapienza University of Rome

47 PUBLICATIONS 145 CITATIONS

[SEE PROFILE](#)



Flavia Longo

Umberto I Policlinico di Roma

170 PUBLICATIONS 4,217 CITATIONS

[SEE PROFILE](#)

Some of the authors of this publication are also working on these related projects:



A-LOC/G-LOC BUSTER [View project](#)



radiotherapy for brain metastases [View project](#)

Multimodality treatment of stage II thymic tumours

Carolina Carillo¹, Daniele Diso¹, Sara Mantovani¹, Ylenia Pecoraro¹, Tiziano De Giacomo¹, Anna Maria Ciccone², Camilla Poggi², Flavia Longo³, Raffaele Cassese⁴, Vincenzo Tombolini⁴, Erino Angelo Rendina², Federico Venuta¹, Marco Anile¹

¹Department of Thoracic Surgery, University of Rome Sapienza, Rome, Italy; ²Department of Thoracic Surgery, Sant'Andrea Hospital, Rome, Italy;

³Department of Medical Oncology, ⁴Department of Radiotherapy, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy

Contributions: (I) Conception and design: F Venuta; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Federico Venuta, MD. Cattedra di Chirurgia Toracica, Policlinico Umberto I, Università di Roma Sapienza, V.le del Policlinico 155, 00161 Roma, Italy. Email: federico.venuta@uniroma1.it.

Background: Complete resection for stage II thymic tumors can be easily accomplished even if the capsula and adjacent mediastinal tissue are macroscopically involved; however, also at this stage, recurrence may occur, particularly for B2, B3 and thymic carcinoma. The criteria for the administration of adjuvant therapy remain controversial and it is unclear whether patients at this stage may benefit from it. We reviewed a series of patients at this stage receiving adjuvant chemo-radiotherapy (chemo-RT) based on histology.

Methods: Eighty-eight consecutive patients with stage II thymic tumors were reviewed; 59 patients (67%) with B thymoma or thymic carcinoma received adjuvant treatment with mediastinal irradiation (40–55 Gy), chemotherapy (CH) (PAC regimen) or a combination of both.

Results: Complete resection was achieved in all patients. Fifty-four patients (61%) received post-operative chemo-RT, 2 (2%) patients received adjuvant CH only and 3 (3%) post-operative RT only; they all had B2, B3 histology or thymic carcinoma. The median follow up was 107±83 months. 5-year and 10-year survival were 96%±2% and 83.4%±5%. Recurrence was observed in 5 patients (5.7%). Disease-free 5 and 10-year survival was 94%±2% and 92%±3% respectively. Five patients (5.7%) had recurrence.

Conclusions: The administration of adjuvant chemo-RT to patients with stage II type B thymoma and thymic carcinoma contributes to reduce the recurrence rate and to increase long-term survival.

Keywords: Thymoma; thymic carcinoma; adjuvant therapy; radiotherapy (RT); chemotherapy (CH); Masaoka stage II

Submitted Nov 24, 2016. Accepted for publication Jun 21, 2017.

doi: 10.21037/jtd.2017.06.116

View this article at: <http://dx.doi.org/10.21037/jtd.2017.06.116>

Introduction

Thymic tumors are relatively rare neoplasms arising from the epithelial thymic cells. They show a significant histological heterogeneity and clinical behavior ranging from an indolent non-invasive attitude to a highly infiltrative and metastasizing one. Prognosis is affected by the Masaoka-Koga staging, the World Health Organization (WHO) histological classification, completeness of resection, the diameter of the lesion and the presence of

vascular invasion (1-8).

Complete surgical resection, remains the gold standard for cure at any stage. Chemotherapy (CH) is usually administered as an induction before surgery or as definitive treatment when the tumor is deemed unresectable. Radiotherapy (RT) is indicated in selected patients, particularly as adjuvant treatment. A multimodality approach is beneficial for a selected group of patients with invasive tumors (9-11).

According to the Masaoka-Koga staging system,

Table 1 Masaoka stage vs. World Health Organization histology

WHO histology	Masaoka stage		Recurrence
	Stage IIA (%)	Stage IIB (%)	
A	7 (20.0)	4 (7.6)	–
AB	8 (22.9)	7 (13.2)	–
B1	1 (2.9)	2 (3.8)	–
B2	10 (28.6)	12 (22.6)	2 (9.1)
B3	7 (20.0)	23 (43.4)	2 (6.7)
Thymic carcinoma	2 (5.6)	5 (9.4)	1 (14.3)
Total	35 (39.8)	53 (60.2)	5 (5.7)

thymic tumors are classified as stage IIA when they show microscopic trans-capsular invasion and IIB in case of macroscopic invasion of the surrounding mediastinal fat tissue or gross adherence to the mediastinal pleura (12,13). Although complete resection can be easily achieved at this stage, local recurrence and metastatic spread may be observed, particularly in case of B2, B3 and thymic carcinoma (6,7,14,15). For this reason, some authors suggest the administration of adjuvant RT to improve local control (16-20). However, the clinical benefit of adjuvant RT in this setting still remains controversial; in fact, not only local recurrence, but also distant metastatic spread may occur. We have previously described our initial experience with adjuvant CH-RT for stage III tumors to prevent local recurrence and distant spreading (9,21-25). Up to 1988 we have treated stage II thymic tumors with surgical resection only; post-operative RT was rarely administered and without standardized indications. We observed a relatively high number of recurrences (33%) and most of them were outside the mediastinum (21,23); for this reason, since 1989 we administer adjuvant CH-RT for stage II—WHO type B thymoma and thymic carcinoma. The aim of this study is to assess the potential benefit of this approach.

Methods

Eighty-eight patients prospectively entered the database between 1989 and 2013. The study was approved by the ethical committee of our institution (prot. 116/10). All tumors were staged according to the Masaoka-Koga system. Histology was assessed according to the WHO histological classification (25).

Forty-seven patients were male (53.4%); the mean age

was 57±16 years (range, 22–87 years) and 32 (36%) were affected by Myasthenia Gravis; one patient had pemphigus and one had hypogammaglobulinemia. Eighteen patients (20.4%) referred tumor-related symptoms as chest pain and tightness; 22 patients (25%) presented comorbidities including arrhythmias (6%), diabetes (9%) and chronic obstructive pulmonary disease (10%). Three patients (3.4%) had a previous history of cancer (breast, prostate and leukemia). Histology and stage are reported in *Table 1*. The median follow-up was 107±83 months, ranging from 8 to 280 months. No patient was lost to follow-up.

According to our protocol, patients with stage IIA tumors and B2, B3 or C histology received adjuvant CH-RT; in case of B1 thymoma adjuvant therapy was administered only for lesions with a diameter >5 cm. In case of stage IIB, all patients with B or C histology underwent adjuvant treatment. CH was administered with three cycles of PAC (cisplatinum 50 mg/m², doxorubicin 50 mg/m², and cyclophosphamide 500 mg/m²); mediastinal RT was administered at a dose between 45 and 55 Gy.

Descriptive statistics were reported as means with ranges and standard deviation for continuous variables and as frequencies and proportions for categorical variables. Disease-free survival (DFS) was defined as the time from surgery to recurrence. Overall survival (OS) was defined as the time from surgery to death by any cause. The Kaplan-Meier method was used to estimate DFS and OS. Results were considered significant for a P value less than 0.05. The statistical analysis was performed with SPSS Statistics 17.0 (IBM®-ITALIA).

Results


Complete resection was achieved in all patients and no perioperative mortality was observed. Surgical data are reported in *Table 2*. Twenty-six patients (29.5%) had type A or AB thymoma and they did not receive any adjuvant treatment. Fifty-four patients (61%) received post-operative CH-RT, including one B1/IIA patient (tumor diameter >5 cm) (*Table 2*); 2 (2%) received adjuvant CH only and 3 (3%) postoperative RT only. Two patients with B2 histology refused any adjuvant treatment. One patient with B3 histology did not receive any adjuvant treatment due to her advanced age (87 years).

Hematologic toxicity was observed in 5 patients with mild temporary leukopenia; non-hematologic toxicity included stomatitis, alopecia, nausea and vomiting. There were no infectious complications. Post RT esophagitis was

Table 2 Treatment and complications of the patients (n=88)


Variable	Number [%]
Induction chemotherapy	2 [2]
Surgery alone	29 [33]
Adjuvant treatment	
Adjuvant CH + RT	54 [61]
Adjuvant CH	2 [2]
Adjuvant RT	3 [3]
Type of surgery	
Sternotomy	78 [89]
Thoracotomy	7 [8]
VATS	3 [3]
Complications	
Pneumothorax	1 [1]
Bleeding	1 [1]
Sternal dehiscence	1 [1]
Myasthenia gravis crisis	1 [1]
Respiratory failure	1 [1]
Deaths	
Tumor related	4 [4]
Other causes	9 [10]

CH, chemotherapy; RT, radiotherapy; VATS, video assisted thoracic surgery.

**Figure 1** Overall survival of the study population.

observed in one patient.

OS and DFS are reported in *Figures 1,2*. Recurrence was observed in 5 patients (5.7%) 105±83 months (range, 8–280 months) after surgery (*Table 1*). One patient had

**Figure 2** Disease free survival of the study population.

mediastinal recurrence and he was treated with CH; two patients had extrathoracic recurrence (retroperitoneal and liver); two showed intrathoracic recurrence (pleural after thoracoscopic thymectomy and lung), both of them underwent re-resection.

During follow-up 13 patients died (15%): 4 of them (4.5%) for disease progression; the others died for non-thymoma related complications [one cardiac failure, two acute myocardial infarction (AMI), one herpetic encephalitis, one metastatic melanoma, four “senectus”]. We did not observe any statistically significant difference in terms of OS between stage IIA and IIB after 1989 (P=0.1).

Discussion

The Masaoka-Koga staging system is based on the detection of microscopic or macroscopic invasion into the capsula of the tumor and adjacent structures and on the presence of metastatic disease. Although for stage II tumors complete resection is always feasible, incomplete resection has been reported and local or distant recurrence may occur. Furthermore, the literature supports the assumption that thymic tumors show a morphologic continuum: some of them may progress from B1 to B3 and even to thymic carcinoma (5,22). These data are sustained also by the finding of different histologies in the same specimen.

In a previous study, in a population of 27 stage IIB patients we observed a relatively high recurrence rate (33%) in the subgroup IIB (21); most of those recurrences

Table 3 Recurrence rate and survival: literature review

Author (reference)	Number of patients	Number at stage II	Number with adjuvant treatment	5-year survival (%) (IA or B) [#]	Stage II recurrence rate (%)	Comments
Regnard (26)	307 ^a	70	54*	100.0 or 74.0 (IA or B) [#]	7 (5/70)	No significant DFS differences with and without postoperative RT
Mangi (27)	155 ^b	49	14*	100 ^{##}	2 (1/49)	Only one recurrence (cortical thymoma) among the 35 stage II group patients who received only surgery (2.9%)
Kondo (3)	100 ^a	26	10 (38%)	100.0	7.7 (2/26)	90% received only RT, 10% CHT
Chen (28)	107 ^b	107	66*	93.8	7.5 (8/107)	Two patients underwent only surgery (1 B1, 1 B3), five patients received post-operative RT (1 A, 1 AB, 3 B3); one received neoadjuvant CHT-RT for an undefined histological subtype
Bae (2)	305 ^b	114	86	89.8 ^{###}	11.4	13 recurrences/114 (3 AB, 1 B1, 1 B2, 8 B3)
Chang (29)	76 ^b	65	50*	70.0 vs. 97.8 ^{##}	6 (4/65)	Three recurrences/15 patients undergoing only surgery (group A); one recurrence/50 patients receiving also RT (group B)
Litvak (30)	121 ^c	13 ^s	9*	81.0	20 (4/20)	Including also seven stage I patients (7 stage I +13 stage II); 69% stage II patients were R0
Saffidine (4)	262 ^b	123	112	95.0 ^{###}	No recurrence	Out of 123 patients with stage II thymoma five received preoperative CHT-RT and 15 were R1 at surgery

^a, including also thymic carcinoma; ^b, excluding thymic carcinoma; ^c, including only patients with thymic carcinoma; ^s, 69% of the patients were R0; [#], 10-year survival; ^{##}, 10-year disease-free survival; ^{###}, overall survival for all stages and histologies; *, only adjuvant radiation. DFS, disease free survival; CHT, chemotherapy; RT, radiotherapy.

were outside the mediastinum (pleura, lung, liver, bone), confirming that even at this stage thymoma can recur and metastasize. For this reason, at that time we postulated that also stage II thymic tumors might benefit from adjuvant treatment. Thus, RT and CH were administered with the aim of reducing local and distant recurrence respectively. The results of our study show that the recurrence rate is decreased and DFS seems improved after adjuvant treatment, when compared to our previous data (23) and the international literature (also when postoperative RT only is administered) (*Table 3*).

Bae showed a recurrence rate of 11.4% (13 out of 114 patients) (2); Detterbeck reported an average recurrence rate of 11% for stage II (31). Both studies included stage II patients and only RT was administered after surgery. Other studies are much more difficult to interpret since a thorough analysis is not always reported: in other words, it is not always clear how many tumors are at stage IIA or IIB as well as the distribution of histology, particularly the incidence of thymic carcinoma; also the exact number of patients at this stage receiving adjuvant RT is difficult to extrapolate. Furthermore, recurrence is not always well reported at this stage. In the present study the overall recurrence rate was 5.7% while it was 33% in our previous series with surgery alone. Recurrence was observed only in type C (1), B3 (2) and B2 (2) (*Table 1*). This finding supports that adjuvant CH-RT might contribute to reduce the recurrence rate also at this stage and particularly for more aggressive histological subtypes. It also confirms that the WHO classification has a prognostic impact on this variable: as a matter of fact recurrence occurs only in type B2-3 and thymic carcinoma patients. In the present series OS is influenced by other causes than tumor (cardiac ischemia or failure, encephalitis, second malignancies, older age) and only 4 patients (4.5%) died for disease progression. The consistency of this data is supported by the long follow-up (107±83 months).

We have observed 9 (10.2%) metachronous extra-thymic malignancies (thyroid, breast, liver, lung, skin, prostate and leukemia); they were associated with B2 and B3 histology. This finding supports the hypothesis that more aggressive histological subtypes are associated with a higher risk of developing other malignancies and poorer survival (32). The potential role of adjuvant treatment in the development of other malignancies deserves further investigation.

Thymic carcinoma is relatively rare (15% to 20% of all thymic tumors) (1,3) and it shows a spectrum of 11 subtypes (25). In most of the cases it behaves aggressively and it is discovered at an advanced stage, with a lower

survival rate (30–60% at 5 years; 17% if unresectable) (33). It is now considered as a separate entity. In our early stage series, we observed only 7 (8%) patients with thymic carcinoma. Considering this group separately, only 1 (14.2%) patient had recurrence; this incidence is low when compared with the current literature (7,27,30) (Table 3). On the other side, excluding type C, the recurrence rate (4/81) was further reduced respect to our previous series not including this histological subtype (4.9% vs. 33%). These results contribute to support a multidisciplinary approach also at this stage. Although the 2015 ESMO guidelines support the administration of postoperative RT only (34), we believe that also CH should be added in this specific subset of patients since in the literature, and also in our previous experience, distant metastases have been observed and reported.

In conclusion, we confirm that A and AB thymoma show an excellent prognosis with no recurrence, whereas B and C tumors are usually more aggressive also at early stage; postoperative CH-RT might contribute to improve prognosis. Nonetheless, this study does not allow definitive conclusions due to the limitations related to the small number of patients, particularly those with thymic carcinoma; however, with all the limitations of this report, it should serve as “food for thought” for future investigations.

Acknowledgements

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The study was approved by the Ethical Committee of the University of Rome Sapienza - Policlinico Umberto I (prot. 116/10). Written informed consent was obtained from the patient.

References

1. Venuta F, Rendina EA, Anile M, et al. Thymoma and thymic carcinoma. *Gen Thorac Cardiovasc Surg* 2012;60:1-12.
2. Bae MK, Lee CY, Lee JG, et al. Predictors of recurrence after Thymoma resection. *Yonsei Med J* 2013;54:875-82.
3. Ruffini E, Detterbeck F, Van Raemdonck D, et al. Thymic carcinoma: a cohort study of patients from the European Society of Thoracic Surgeons database. *J Thorac Oncol* 2014;9:541-8.
4. Safieddine N, Liu G, Cuningham K, et al. Prognostic factors for cure, recurrence and long-term survival after surgical resection of thymoma. *J Thorac Oncol* 2014;9:1018-22.
5. Ströbel P, Marx A, Zetl A, et al. Thymoma and thymic carcinoma: an update of the WHO Classification 2004. *Surg Today* 2005;35:805-11.
6. Okumura M, Ohta M, Tateyana H, et al. The World Health Organization histologic classification system reflects the oncologic behaviour of thymoma: a clinical study of 273 patients. *Cancer* 2002;94:624-32.
7. Kondo K, Yoshizawa K, Tsuyuguchi M, et al. WHO histologic classification is a prognostic indicator in thymoma. *Ann Thorac Surg* 2004;77:1183-8.
8. Guerrero F, Rendina EA, Venuta F, et al. Does the World Health Organization histological classification predict outcomes after thymomectomy? Results of a multicenter study on 750 patients. *Eur J Cardiothorac Surg* 2015;48:48-54.
9. Venuta F, Rendina EA, Longo F, et al. Long-term outcome after multimodality treatment for stage III thymic tumors. *Ann Thorac Surg* 2003;76: 1866-72.
10. Leuzzi G, Rocco G, Ruffini E, et al. Multimodality therapy for locally advanced thymomas: a propensity score-matched cohort study from the European Society of Thoracic Surgeons Database. *J Thorac Cardiovasc Surg* 2016;151:47-57.e1.
11. Venuta F, Anile M, Rendina EA, et al. The value of transcapsular invasion in patients with thymoma. *Arch Pathol Lab Med* 2009;133:1364-5.
12. Detterbeck FC, Nicholson AG, Kondo K, et al. The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms. *J Thorac Oncol* 2011;6:S1710-6.
13. Nicholson AG, Detterbeck FC, Marino M, et al. The IALSC-ITMIG thymic epithelial tumors staging project: proposals for the T component for the forthcoming (8TH) edition of the TNM classification of malignant tumors. *J Thorac Oncol* 2014;9:S73-80.
14. Haniuda M, Kondo R, Numanami H, et al. Recurrence of thymoma: clinicopathological features, re-operation and outcome. *J Surg Oncol* 2001;78:183-8.
15. Gripp S, Hilgers K, Wurm R, et al. Thymoma: prognostic factors and treatment outcomes. *Cancer* 1998;83:1495-503.
16. Berman AT, Litzky L, Livolsi V, et al. Adjuvant

- radiotherapy for completely resected stage II thymoma. *Cancer* 2011;117:3502-8.
17. Jackson MA, Ball DL. Post-operative radiotherapy in invasive thymoma. *Radiother Oncol* 1991;21:77-82.
 18. Curran WJ Jr, Kornstein MJ, Brooks JJ, et al. Invasive thymoma: the role of mediastinal irradiation following complete and incomplete surgical resection. *J Clin Oncol* 1988;6:1722-27.
 19. Ogawa K, Toita T, Kakinohana Y, et al. Postoperative radiation therapy for completely resected invasive thymoma: prognostic value of pleural invasion for intrathoracic control. *Jpn J Clin Oncol* 1999;29:474-8.
 20. Nakahara K, Ohno K, Hashimoto J, et al. Thymoma: results with complete resection and adjuvant postoperative irradiation in 141 consecutive patients. *J Thorac Cardiovasc Surg* 1988;95:1041-7.
 21. Pescarmona E, Rendina EA, Venuta F, et al. Analysis of prognostic factors and clinic-pathological staging of thymoma. *Ann Thorac Surg* 1990;50:534-8.
 22. Pescarmona E, Rendina EA, Venuta F, et al. Recurrent thymoma: evidence for histological progression. *Histopathology* 1995;27:445-9.
 23. Venuta F, Rendina EA, Pescarmona E, et al. Multimodality treatment of thymoma: a prospective study. *Ann Thorac Surg* 1997;64:1585-91.
 24. Ruffini E, Van Raemdonck D, Detterbeck F, et al. Management of thymic tumors: a survey of current practice among members of the European Society of Thoracic Surgeons. *J Thorac Oncol* 2011;6:614-23.
 25. Travis WD, Brambilla E, Muller-Hermelink HK, et al. WHO classification of tumors, pathology and genetics of tumors of the lung, pleura, thymus and heart. Lyon: IARC PRESS, 2004:152-3.
 26. Regnard JF, Magdeleinat P, Dromer C, et al. Prognostic factors and long term results after thymoma resection: a series of 307 patients. *J Thorac Cardiovasc Surg* 1996;112:376-84.
 27. Mangi AA, Wright CD, Allan JS, et al. Adjuvant radiation therapy for stage II thymoma. *Ann Thorac Surg* 2002;74:1033-37.
 28. Chen YD, Feng QF, Lu HZ, et al. Role of adjuvant radiotherapy for stage II thymoma after complete tumor resection. *Int J Radiat Oncol Biol Phys* 2010;78:1400-6.
 29. Chang JH, Kim HJ, Wu HG, et al. Postoperative radiotherapy for completely resected stage II or III thymoma. *J Thorac Oncol* 2011;6:1282-6.
 30. Litvak AM, Woo K, Hayes S, et al. Clinical characteristic and outcomes for patients with thymic carcinoma – evaluation of Masaoka staging. *J Thorac Oncol* 2014;9:1810-5.
 31. Detterbeck FC. Evaluation and treatment of stage I and II thymoma. *J Thorac Oncol* 2010;5:S318-22.
 32. Filosso PL, Galassi C, Ruffini E, et al. Thymoma and the increased risk of developing extrathymic malignancies: a multicentre study. *Eur J Cardiothorac Surg* 2013;44:219-24; discussion 224.
 33. Okuma Y, Hosomi Y, Takagi Y, et al. Clinical outcomes with chemotherapy for advanced thymic carcinoma. *Lung cancer* 2013;80:75-80.
 34. Girard N, Ruffini E, Marx A, et al. Thymic epithelial tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow up. *Ann Oncol* 2015;26:v40-55.

Cite this article as: Carillo C, Diso D, Mantovani S, Pecoraro Y, De Giacomo T, Ciccone AM, Poggi C, Longo F, Cassese R, Tombolini V, Rendina EA, Venuta F, Anile M. Multimodality treatment of stage II thymic tumours. *J Thorac Dis* 2017;9(8):2369-2374. doi: 10.21037/jtd.2017.06.116